Core Viewpoint - Shanghai MicroPort CardioFlow Medtech Co., Ltd. reported a strong financial performance for the year 2025, with significant growth in revenue and net profit, indicating a positive outlook for the company and its market position [1]. Financial Performance - The company achieved total revenue of 1.351 billion yuan, representing a year-on-year increase of 11.96% [1]. - The net profit attributable to shareholders was 563 million yuan, up 12.17% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was 502 million yuan, reflecting a substantial growth of 26.97% [1]. - Basic earnings per share reached 4.65 yuan, an increase of 14.25% compared to the previous year [1]. Asset and Equity Growth - Total assets amounted to 4.640 billion yuan, showing an 8.13% increase from the beginning of the year [1]. - The equity attributable to shareholders of the parent company was 4.076 billion yuan, which is a 7.48% growth since the start of the year [1]. Market Expansion - The company has accelerated its overseas market expansion, with overseas revenue exceeding 250 million yuan, marking a growth of over 55% [1]. - Products are now sold in 49 countries and regions, indicating a broadening international presence [1].

人民财讯2月27日电，心脉医疗(688016)2月27日发布业绩快报，2025年实现营业总收入13.51亿元，同比 增长11.96%；归母净利润5.63亿元，同比增长12.17%；基本每股收益4.65元。报告期内，公司创新产品 在巩固国产领先优势的基础上，通过下沉市场、提供定制化治疗方案以及产品升级迭代，加速推广新 品、替换老产品等策略，推动市占率稳步提升，但考虑到2024年市场价格治理因素影响的延续性，公司 部分产品价格及推广策略的调整因素，全年销售额增速及利润仍受到一定影响。 ...